• Explore /
  • Poster
  • / A phase 1, first-in-human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors.

A phase 1, first-in-human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors.

Abstract Poster

Authors

null

Kim Anna Reiss

University of Pennsylvania Abramson Cancer Center, Philadelphia, PA

Kim Anna Reiss , Yuan Yuan , Debora Barton , Daniel Cushing , Amy Ronczka , Michael Klichinsky , Elizabeth Claire Dees

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04660929

DOI

10.1200/JCO.2022.40.4_suppl.TPS668

Abstract #

TPS668

Poster Bd #

M10

Abstract Disclosures

Similar Posters

First Author: Joshua Bauml

First Author: Kim Anna Reiss

First Author: Behnam Badie

First Author: Shanshan Jin